非小细胞肺癌脑转移放化疗联合治疗的临床观察  

Clinical efficacy of whole brain radiotherapy and Topotecan/cisplatin regimen to treat non-small cell lung cancer

作　　者：翟福林 

机构地区：[1]郴州第一人民医院南院肿瘤科,湖南郴州423000

出　　处：《湘南学院学报（医学版）》2012年第2期18-20,共3页Journal of Xiangnan University（Medical Sciences）

摘　　要：目的评价Topotecan联合顺铂方案(TPTP方案)治疗非小细胞肺癌脑转移的临床疗效。方法 64例非小细胞肺癌伴情转移的患者随机分两组,全脑放疗后给予TPTP方案或GP方案化疗2～4周期,观察患者对该方案的疗效及毒性反应。结果 TPTP方案组脑部病灶客观有效率59.38%,肺部病灶的有效率为62.50%。GP办案组脑部病灶客观有效率53.13%,肺部病灶的有效率为56.25%,TPTP方案组有效率高于GP组,两组之间差异有统计学意义(P=0.023)。毒性反应TPTP方案组腹泻、脱发发生率高,GP方案组血小板减少发生率高,组间有统计学差异(P<0.05),但均可耐受。结论 Topotecan联合顺铂方案是一种有效的治疗非小细胞肺癌脑转移的化疗方案。Objective To evaluate the clinical efficacy of Topotecan/cisplatin regimen to treat brain metastasis with non - small cell lung cancer. Methods 64 cases brain metastasis with Advanced non - small cell lung cancer, The patients were random divided into two groups. 32 previously untreated patients with brain metastasis of non - small cell lung cancer were treated by whole brain radiotherap and Topoteean/cisplatin regimen. 32 others were treated by whole brain radiotherap and gemcitabine/cisplatin regimen. Results The Topotecan/cisplatin treatment achieved a significant proportion of response rate from brain MRI/CTscan. TFFP group, the brain response rate was59.38% ,the lung response rate was62.50%, that of GP group was53.13% ,56.25%. between two groups had significant difference（P = 0. 023）. The major toxic and side effects, leukopenia and thromboeytopenia were not increased. Then there was no significant difference of response rate between group （ P 〉 0.05）. Conclusion The Topotecan/cisplatin is avalid chemotherapy regimen to treat brain metastasis patients with non - small cell lung cancer.

关 键 词：TOPOTECAN 非小细胞肺癌 脑转移 

分 类 号：R734.2[医药卫生—肿瘤]